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M A J O R A R T I C L E
Anatomic Fat Depots and Coronary Plaque Among
Human Immunodeficiency Virus-Infected and Uninfected
Men in the Multicenter AIDS Cohort Study
Frank J. Palella Jr.,1 Rebeccah McKibben,2 Wendy S. Post,2 Xiuhong Li,2 Matthew Budoff,3 Lawrence Kingsley,4 Mallory D. Witt,3 Lisa P. Jacobson,2
and Todd T. Brown2
1Northwestern University, Chicago, Illinois; 2Johns Hopkins University, Baltimore, Maryland; 3Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California; and
4University of Pittsburgh, Pennsylvania
Methods. In a cross-sectional substudy of the Multicenter AIDS Cohort Study, noncontrast cardiac computed tomography (CT)
scanning for coronary artery calcium (CAC) scoring was performed on all men, and, for men with normal renal function, coronary
CT angiography (CTA) was performed. Associations between fat depots (visceral adipose tissue [VAT], abdominal subcutaneous
adipose tissue [aSAT], and thigh subcutaneous adipose tissue [tSAT]) with coronary plaque presence and extent were assessed
with logistic and linear regression adjusted for age, race, cardiovascular disease (CVD) risk factors, body mass index (BMI), and
human immunodeficiency virus (HIV) parameters.
Results. Among HIV-infected men (n = 597) but not HIV-uninfected men (n = 343), having greater VAT was positively asso-
ciated with noncalcified plaque presence (odds ratio [OR] = 1.04, P < .05), with a significant interaction (P < .05) by HIV serostatus.
Human immunodeficiency virus-infected men had lower median aSAT and tSAT and greater median VAT among men with BMI
<25 and 25–29.9 kg/m2. Among HIV-infected men, VAT was positively associated with presence of coronary plaque on CTA after
adjustment for CVD risk factors (OR = 1.04, P < .05), but not after additional adjustment for BMI. There was an inverse association
between aSAT and extent of total plaque among HIV-infected men, but not among HIV-uninfected men. Lower tSAT was associated
with greater CAC and total plaque score extent regardless of HIV serostatus.
Conclusions. The presence of greater amounts of VAT and lower SAT may contribute to increased risk for coronary artery dis-
ease among HIV-infected persons.
Keywords. adiposity; coronary plaque.
In the general population, greater amounts of visceral adipose
tissue (VAT) have been associated with pro-atherogenic lipids
abnormalities [1, 2], greater insulin resistance [3], and coronary
artery disease (CAD) [4]. Human immunodeficiency virus
(HIV)-infected persons experience changes in body fat amount
and distribution that have given rise to a characteristic anthro-
pomorphic phenotype and include greater VAT as well as less
subcutaneous abdominal and limb fat [5–7], commonly re-
ferred to as lipodystrophy. These anatomic fat alterations may
impact risk for CAD. In this population, greater VAT and de-
creased subcutaneous fat have been associated with both pro-
atherogenic serum lipid profiles and insulin resistance [8, 9]
but only inconsistently with coronary artery plaque (particular-
ly calcified plaque [CP]) or cardiovascular disease (CVD) clin-
ical events [10, 11]. Causes for these HIV-related body fat
changes are not entirely clear, but they are likely multifactorial.
Factors with established positive associations with VAT and/or
subcutaneous fat include duration of HIV infection, exposure to
specific antiretroviral (ART) therapies (particularly use of thy-
midine analog reverse-transcriptase inhibitors and protease in-
hibitors), and patient age [12–21]. Increases in and duration of
(1) systemic inflammation and (2) immune activation and host
genetics are also postulated to be operative in the pathogenesis
of HIV-associated body fat changes, and these factors contrib-
ute to CAD risk in the general population [22, 23].
Coronary computed tomography angiography (CTA) allows
assessment of the presence, extent, and composition of coro-
nary artery plaque. Using this technique, our group [24] and
others [25] have demonstrated greater overall prevalence of cor-
onary plaque and the presence and extent of noncalcified pla-
que (NCP) among HIV-infected versus uninfected persons. We
hypothesized that regional adiposity is associated with coronary
plaque, but that these associations may differ by HIV serostatus.
We evaluated associations between coronary plaque (overall and
by type and amount), body fat depots assessed by computed
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tomography (CT) imaging, and HIV serostatus among Multi-
center AIDS Cohort Study (MACS) participants.
METHODS
Population
The MACS is an ongoing prospective cohort study of the natu-
ral and treated histories of HIV-1 infection among men who
have sex with men, conducted in the Baltimore andWashington
DC areas, Chicago, Pittsburgh, and Los Angeles [26]. Initial en-
rollment occurred in 1984–1985, with additional enrollment in
1987–1991 and 2001–2003. The cohort includes both HIV-
infected and HIV-uninfected men who attend semiannual
research visits that include standardized interviews, physical ex-
aminations, and blood and urine collection for laboratory
measurements.
The MACS cardiovascular ancillary study participants were
40–70 years of age, weighed <300 pounds, and had no prior his-
tory of cardiac surgery or percutaneous coronary intervention.
All participants completed noncontrast cardiac CT scanning
for coronary artery calcium (CAC) scoring. Men with atrial
fibrillation, chronic kidney disease (estimated glomerular filtra-
tion rate [GFR] in mL/min/m2 of <60 during a prior MACS
study visit), or a history of intravenous contrast allergy were
excluded from CTA studies. All eligible CTA participants had
an estimated GFR >60 within 1 month of CTA. The study
was approved by the Institutional Review Boards of all partici-
pating sites. All participants signed informed consent.
Computed Tomography Scanning and Analysis Procedures
Details of the cardiac CT scanning procedures have been de-
scribed [27]. Abdominal subcutaneous and visceral adiposity
measures were obtained by the addition of 1 noncontrast ab-
dominal CT slice at the level of the umbilicus, corresponding
to the L4 to L5 vertebral level, as previously described [28].
To evaluate thigh fat, a single slice scan was performed at 15
cm above the patellar apex.
Computed tomography images were transferred to the core
CT reading center (Los Angeles Biomedical Research Institute
at Harbor-UCLA) and were analyzed by trained, experienced
readers who were blinded to participant characteristics and
HIV serostatus [28]. Amounts of extra-abdominal (subcutane-
ous) fat were calculated by subtracting intra-abdominal fat from
total abdominal fat. For thigh adiposity, manual tracings were
performed to delineate subcutaneous fat and muscle compart-
ments; muscle attenuation was measured in Hounsfield Units
(HU). Areas of thigh fat, expressed in square centimeters, were
calculated by summing the area of pixels in the slice with CT
values from −150 to −50 HU.
Cardiac Computed Tomography
Coronary artery calcium was calculated using the Agatston
method. The total plaque score (TPS) was calculated by sum-
ming the plaque size score for all assessable coronary segments
that demonstrated any plaque (either CP, NCP, or mixed plaque
[MP]) up to a maximum score of 45. Plaque was graded as 0, 1,
2, or 3 in each segment (15 segments) based on the size of the
plaque. The segment involvement score was calculated as the
sum of coronary artery segments with plaque, regardless of de-
gree of stenosis. Each coronary segment was classified as normal
or containing NCP, MP (<50% of plaque area occupied by cal-
cium), or CP. Calcified atherosclerotic plaque was defined as
any structure with attenuation >130 HU visualized separately
from the intravascular lumen, identified in at least 2 indepen-
dent planes. Noncalcified atherosclerotic plaque was defined
as any discernible structure that could be clearly assignable to
the vessel wall, with a CT density less than the contrast-
enhanced coronary lumen but greater than the surrounding
connective tissue, and identified in at least 2 independent
planes. The NCP score, MP score, and CP score were calculated
by summing the plaque scores in each NCP, MP, or CP segment
separately.
Clinical Parameters
Participants were seen every 6 months at routine MACS re-
search visits. Data were collected regarding CVD risk factors
and HIV clinical parameters by history, physical examination,
and blood tests. For this analysis, data were used that had
been collected at the MACS study visit closest to the CT scan
(within 6 months). Race or ethnicity was based on self-report.
Glucose and serum lipids were measured from fasting samples.
The Modification of Diet in Renal Disease equation was used to
estimate GFR [29].
Hypertension was defined as systolic blood pressure (BP)
>140 mm Hg or diastolic BP >90 mm Hg or self-reported use
of antihypertensive medication. Diabetes mellitus was defined
as fasting serum glucose ≥126 mg/dL or use of medications to
treat diabetes. Measures of HIV disease activity in HIV-infected
men included plasma HIV ribonucleic acid (RNA) levels, CD4+
T lymphocyte counts, history of an acquired immune deficiency
syndrome (AIDS)-defining malignancy or opportunistic infec-
tion, and duration of highly active anti-retroviral therapy
(HAART) use.
Statistical Analysis
The distributions of demographic and clinical factors in HIV-
infected and -uninfected men were compared using the Wilcoxon
rank-sum test or χ2 test. Associations between individual ana-
tomic fat depots (VAT, abdominal subcutaneous fat [aSAT],
and thigh subcutaneous fat [tSAT]) and the presence of coro-
nary artery plaque were assessed using logistic regression.
Plaque was dichotomized as present or absent with plaque pres-
ence defined as a score >0. Models were performed with adjust-
ment for age, race or ethnicity, and established CVD risk factors
(use of hypertension medications, systolic BP among those who
were not on hypertension medications, use of diabetes medica-
tions, fasting glucose among those who were not on diabetes
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medications, use of lipid-lowering medications, total and high-
density lipoprotein (HDL) cholesterol among those who did not
use lipid-lowering medications, pack-years of tobacco smok-
ing). A second model additionally adjusted for body mass
index (BMI). Among HIV-infected men, fully adjusted models
included adjustment for HIV clinical parameters (CD4+ T-cell
count [most recent and nadir], plasma HIV RNA level, history
of AIDS-defining illness, duration of HAART). Linear regres-
sion was used to assess associations between individual anatom-
ic fat depots (VAT, aSAT, and tSAT) with plaque extent among
individuals with plaque present (ie, plaque score >0) for scores
of CAC, TP, CP, MP, and NCP after adjusting for age and race
and CVD risk factors and then additionally for BMI as de-
scribed above. Because plaque scores were not normally distrib-
uted, these values were natural-log transformed. All models
included HIV-infected and uninfected men and were also per-
formed stratified by HIV serostatus. Testing for interaction by
HIV serostatus was also performed. Multiple imputation was
used to complete missing CVD risk factor data for multivariate
models. Missing values were imputed 5 times based on the dis-
tribution of covariates (age, race, HIV serostatus, BMI, cumula-
tive pack years, hypertension medications, systolic BP, diabetes
medications, fasting glucose, lipid-lowering medications, HDL,
and total cholesterol) using a Markov chain Monte Carlo meth-
od [30] assuming multivariate normality. Values for the follow-
ing number of men were missing and imputed for multiple
regression analyses: hypertension medications (2), BMI (3), di-
abetes medications (4), smoking pack-years (8), lipid medica-
tions (11), total and HDL cholesterol (16), systolic BP (26),
fasting glucose (37).
All statistical analyses were performed using SAS 9.2 (SAS
Institute, Cary, NC). Statistical significance was established at a
P value <.05.
RESULTS
Participant Characteristics
There were 597 HIV-infected men and 343 HIV-uninfected
men included in the analysis (Table 1). Compared with HIV-
uninfected men, HIV-infected men were younger with lower
BMI, more likely to be black, and more likely to have hyperten-
sion and diabetes mellitus. Men infected with HIV were also
more likely to be current smokers and have lower levels of
low-density lipoprotein cholesterol, HDL cholesterol, and
total cholesterol, and higher triglyceride levels, and they were
more likely to be receiving lipid-lowering medication (Table 1).
Among HIV-infected men, 18.8% had a detectable plasma
HIV RNA level. The median CD4+ T-cell count at the MACS
visit prior to coronary imaging was 600 cells/mm3 (interquartile
range [IQR], 422–751), and the median CD4+ T-cell count
nadir was 244 cells/mm3 (IQR, 133–331). The mean time
spent receiving HAART was 10.9 ± 4.3 years, and the propor-
tion of men with a history of AIDS was 14.2% (Table 1).
Anatomic Fat Depots
Compared with HIV-uninfected men, HIV-infected men had
lower median aSAT (181 cm2 [IQR, 111–277] vs 233 cm2
[IQR, 169–318], P < .001) and tSAT (26 cm2 [IQR, 13–46] vs
49 cm2 [IQR, 35–67], P < .001) (Table 2). Within each of the
3 BMI categories (<25, 25–29.9, and ≥30 kg/m2), differences
in median fat area by HIV serostatus were observed (Table 3).
Within the BMI <25 kg/m2 and overweight (BMI 25–29.9 kg/m2)
strata, median VAT areas were greater among HIV-infected than
uninfected men (P < .001 and P = .002 for BMI <25 kg/m2, and
BMI 25–29.9 kg/m2, respectively). In all BMI strata, aSAT and
tSAT volumes were significantly lower among HIV-infected
than HIV-uninfected men (all P < .05).
Coronary Plaque
As previously reported, compared with HIV-uninfected men,
HIV-infected men were more likely to have coronary plaque
present (Table 2). Coronary plaque was present in 77.5% of
Table 1. Characteristics of Study Population, Mean ± SD or Prevalence (%)
Characteristic
HIV-
Infected
HIV-
Uninfected P Valuea
N 597 343
Age (years) 53.3 ± 6.5 55.7 ± 7.3 <.001
Race (%) White 52.6 65.9 <.001
African American 33.8 26.0
Hispanic +Other 13.6 8.2
Body Mass Index (kg/m2) 26.1 ± 4.5 27.3 ± 4.8 <.001
Hypertension (%) 49.0 45.5 .31
Antihypertensive medication (%) 35.9 32.8 .34
Systolic blood pressure (mm Hg) 126 ± 15 128 ± 15 .13
Diabetes (%) 13.4 9.9 .12
Diabetes medications (%) 9.4 7.3 .28
Smoking Status (%) <.001
Current 31.8 21.8
Former 43.5 52.4
Never 24.7 25.8
Cumulative smoking pack yearsb 5.9 (0–23.0) 1.5 (0–20.8) .01
Glucose (mg/dL) 102 ± 25 101 ± 29 .07
Total cholesterol (mg/dL) 189 ± 43 191 ± 36 .33
LDL cholesterol (mg/dL) 105 ± 36 112.0 ± 32.2 .003
HDL cholesterol (mg/dL) 48.7 ± 16.6 53.6 ± 16.1 <.001
Triglycerides (mg/dL) 176 ± 133 122 ± 69 <.001
Lipid-lowering medications (%) 36.3 30.4 .07
HIV Parameters
HIV RNA detectable
(>50 copies/mL, % of men)
18.8 —
CD4+ T cell count (cells/mm3)b 600 (422–751) —
CD4+ T cell count nadir
(cells/mm3)b
244 (133–331) —
Time on HAART (years) 10.9 ± 4.3 —
History of AIDS (%) 14.2 —
Abbreviations: AIDS, acquired immune deficiency syndrome; HAART, highly active
antiretroviral therapy; HDL, high-density lipoprotein; HIV, human immunodeficiency virus;
LDL, low-density lipoprotein; RNA, ribonucleic acid; SD, standard deviation.
a By non-parametric Wilcoxon test or χ2 test, as appropriate.
b Median (interquartile range).
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HIV-infected men versus 74.1% of HIV-uninfected men, NCP
(63.8% vs 53.3%), MP (34.9% vs 30.7%), and any coronary ar-
tery luminal stenosis >50% (16.7% vs 14.2%) (Table 2). There
were no differences by HIV serostatus in median plaque scores
for TP, CP, and MP, but greater NCP in HIV-infected men.
Anatomic Fat Depots and Coronary Plaque
Presence of Coronary Plaque
The presence of coronary plaque is outlined in Table 4.
Visceral Adipose Tissue
We analyzed associations between VAT and the presence and
extent of coronary plaque. Visceral adipose tissue was positively
associated with the presence of NCP, in models that adjusted for
age, race, and CVD risk factors (Model 1), or for age, race, CVD
risk factors, and BMI (Model 2) (P < .05 for all) among HIV-
infected men but not among HIV-uninfected men (Table 4
and Figure 1). However, there were significant interactions by
HIV serostatus in both analytic models (P < .05 for all). Visceral
adipose tissue was positively associated with the presence of
NCP in both models.
Although coinfection with HIV and chronic hepatitis C virus
(HCV) was significantly associated with NCP presence, adding
HCV to the fully adjusted analytic model (Model 2) did not
alter the significant relationship between VAT and NCP pres-
ence. Adding CVD risk scores (calculated using the 2013 Amer-
ican College of Cardiology/American Heart Association
Guidelines) to fully adjusted models did not alter the relation-
ship between VAT and NCP presence.
Although no statistically significant HIV interactions existed,
among HIV-infected men VAT was positively associated with
“any coronary plaque” presence in Model 1 (P < .05) but not
after additional adjustment including BMI (Model 2). No asso-
ciations existed between VAT and the presence of any coronary
plaque among HIV-uninfected men.
No significant interactions by HIV serostatus and no associ-
ations between VAT and CAC presence existed in analyses strat-
ified by HIV serostatus. After adjustment for CVD risk factors
and BMI, no associations between VAT and presence of coro-
nary stenosis >50% among HIV-infected men existed.
Abdominal Subcutaneous Adipose Tissue and Thigh Subcutaneous
Adipose Tissue
No significant associations were seen between either aSAT or
tSAT and the presence of any coronary plaque type or stenosis
among either HIV-infected and -uninfected men.
Extent of Coronary Plaque
Visceral Adipose Tissue
Among men with coronary plaque present VAT was not associ-
ated with the extent of coronary plaque of any type, regardless
of HIV serostatus (Table 5).
Table 2. Characteristics of Anatomic Fat Depots and Coronary Plaque,
Median (IQR)
Fat Depot, or Coronary Plaque
Characteristic
HIV-
Infected
HIV-
Uninfected P Valuea
Abdominal visceral fat (VAT)
(cm2), N
596 341
Median (IQR) 150 (87–218) 139 (88–207) .33
Abdominal subcutaneous fat
(aSAT) (cm2), N
596 341
median (IQR) 181 (111–277) 233 (169–318) <.001
Thigh subcutaneous fat
(tSAT) (cm2), N
596 342
median (IQR) 26 (13–46) 49 (35–67) <.001
Coronary artery Calcium score
(CAC), N
597 342
prevalence with CAC >0, N (%) 315 (52.8) 173 (50.6) .52
Median (IQR) 3 (0–81) 1 (0–72) .61
Coronary CT angiography, N 436 274
Prevalence of any coronary
plaque, N (%)
338 (77.5) 203 (74.1) .29
Prevalence of calcified
plaque, N (%)
149 (34.2) 104 (38.0) .31
Prevalence of noncalcified
plaque, N (%)
278 (63.8) 146 (53.3) .006
Prevalence of mixed plaque, N (%) 152 (34.9) 84 (30.7) .25
Prevalence of any coronary artery
stenosis >50%, N (%)
73 (16.7) 39 (14.2) .37
Total Plaque Score
Median (IQR) 2 (1–5) 2 (0–5) .16
Calcified Plaque Score
Median (IQR) 0 (0–1) 0 (0–1) .17
Noncalcified Plaque Score
Median (IQR) 1 (0–3) 1 (0–2) .001
Mixed Plaque Score
Median (IQR) 0 (0–1) 0 (0–1) .16
Abbreviations: aSAT, abdominal subcutaneous adipose tissue; CAC, coronary artery calcium
score; CT, computed tomography; HIV, human immunodeficiency virus; IQR, interquartile
range; tSAT, thigh subcutaneous adipose tissue; VAT, visceral adipose tissue.
a By non-parametric Wilcoxon test or χ2 test, as appropriate.
Table 3. Anatomic Fat Depots by BMI (in kg/m2) Categories and HIV-
Serostatus, Adjusted for Age and Race
Fat Depot and BMI
Category
HIV-Infected HIV-Uninfected
P
ValueN Median (IQR) N Median (IQR)
Abdominal Visceral Fat
BMI < 25 kg/m2 278 115 (76–158) 126 88 (57–132) <.001
25–29.9 kg/m2 196 170 (124–220) 131 155 (112–210) .002
≥30 kg/m2 115 233 (184–291) 81 244 (175–285) .88
Abdominal Subcutaneous Fat
BMI < 25 kg/m2 278 119 (75–168) 126 152 (120–196) <.001
25–29.9 kg/m2 196 215 (160–281) 131 249 (205–284) <.001
≥30 kg/m2 115 356 (287–438) 81 403 (332–492) .02
Thigh Subcutaneous Fat
BMI < 25 kg/m2 278 18 (9–29) 127 37 (26–45) <.001
25–29.9 kg/m2 196 29 (19–48) 131 49 (39–60) <.001
≥30 kg/m2 115 56 (36–84) 81 81 (69–112) <.001
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; IQR,
interquartile range.
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Table 4. Associations Between Body Fat Depots and Presence of Coronary Plaque (Score >0) and Coronary Artery Stenosis >50%
Plaque Type, Analytic Model
Visceral Adipose Tissue Abdominal Subcutaneous Adipose Tissue Thigh Subcutaneous Adipose Tissue (tSAT)
All (N = 937) HIV+ (N = 596) HIV− (N = 341) All (N = 937) HIV+ (N = 596) HIV− (N = 341) All (N = 938) HIV+ (N = 596) HIV− (N = 342)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
CAC
Model 1 1.00 (.98–1.02) 1.00 (.98–1.02) 0.99 (.96–1.02) 1.00 (.99–1.01) 0.99 (.98–1.01) 1.00 (.98–1.03) 1.00 (.95–1.06) 0.99 (.92–1.06) 1.03 (.94–1.12)
Model 2 0.99 (.97–1.02) 1.00 (.98–1.03) 0.97 (.92–1.01) 0.99 (.96–1.01) 0.99 (.96–1.01) 0.99 (.95–1.02) 0.99 (.93–1.06) 0.99 (.90–1.08) 1.00 (.88–1.13)
Noncalcified Plaque (NCP)a,b
Model 1 1.02c (1.00–1.04) 1.04* (1.01–1.07) 0.99 (.96–1.03) 1.00 (.99–1.01) 1.00 (.99–1.02) 0.99 (.97–1.02) 1.01 (.95–1.07) 1.04 (.96–1.12) 0.99 (.91–1.07)
Model 2 1.02d (.99–1.05) 1.04* (1.00–1.08) 0.99 (.95–1.03) 0.98 (.96–1.00) 0.98 (.95–1.01) 0.98 (.95–1.02) 0.98 (.91–1.05) 1.00 (.90–1.11) 0.96 (.85–1.09)
Calcified Plaque (CP)a,b
Model 1 1.04 (.98–1.02) 1.01 (.98–1.04) 0.99 (.95–1.02) 1.00 (.99–1.02) 1.00 (.99–1.02) 0.99 (.97–1.02) 1.02 (.96–1.08) 1.04 (.96–1.13) 0.96 (.87–1.06)
Model 2 0.99 (.97–1.02) 1.00 (.97–1.04) 0.98 (.94–1.03) 0.99 (.97–1.02) 0.99 (.96–1.02) 0.98 (.94–1.03) 1.00 (.92–1.09) 1.02 (.92–1.14) 0.93 (.80–1.08)
Mixed Plaque (MP)a,b
Model 1 1.00 (.98–1.02) 1.00 (.98–1.03) 0.99 (.96–1.03) 0.99 (.98–1.00) 0.99 (.97–1.01) 0.99 (.97–1.02) 0.98 (.92–1.04) 0.98 (.90–1.06) 0.98 (.89–1.08)
Model 2 1.01 (.98–1.04) 1.01 (.98–1.05) 1.00 (.96–1.05) 0.99 (.96–1.01) 0.98 (.95–1.01) 1.01 (.97–1.05) 1.00 (.92–1.08) 0.99 (.89–1.10) 1.04 (.89–1.20)
Total Plaque Scorea,b
Model 1 1.02 (.99–1.05) 1.04* (1.00–1.08) 0.99 (.95–1.04) 1.01 (.99–1.02) 1.01 (.99–1.03) 1.00 (.98–1.03) 1.05 (.98–1.12) 1.05 (.96–1.16) 1.03 (.92–1.14)
Model 2 1.02 (.98–1.05) 1.04 (.995–1.09) 0.98 (.93–1.04) 0.99 (.97–1.02) 0.99 (.96–1.02) 1.00 (.96–1.04) 1.04 (.95–1.14) 1.03 (.91–1.16) 1.04 (.89–1.22)
Stenosis >50%a,b
Model 1 0.99 (.97–1.02) 0.98 (.94–1.01) 1.02 (.97–1.07) 0.99 (.97–1.01) 0.98 (.96–1.01) 1.01 (.97–1.04) 1.00 (.93–1.09) 1.00 (.89–1.11) 1.01 (.89–1.15)
Model 2 0.99 (.96–1.03) 0.98 (.94–1.02) 1.01 (.95–1.07) 0.98 (.95–1.01) 0.98 (.94–1.02) 0.99 (.93–1.04) 1.01 (.91–1.12) 1.04 (.91–1.19) 0.92 (.76–1.13)
Abbreviations: BMI, bodymass index; CAC, coronary artery calcium score; CI, confidence interval; CP, calcified plaque score; CTA, computed tomography angiography; CVD, cardiovascular disease; HIV, human immunodeficiency virus; MP, mixed plaque score;
NCP, noncalcified plaque score.
(NOTE: Model 1 adjusted for age, race, and CVD risk factors. Model 2 adjusted for age, race, CVD risk factors, and BMI. OR = odds ratio per 10-units increase in fat volume. For HIV-infected participants, model 2 additionally adjusted for HIV-related factors.)
a Sample size for coronary CTA measurements: all = 707, HIV+ = 435, HIV−= 272.
b Within tSAT analysis, sample size: all = 708, HIV+ = 435, HIV− = 273.
c HIV interaction P < .05.
d HIV interaction P≤ .01.
*P < .05; **P < .01.
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Abdominal Subcutaneous Adipose Tissue and Thigh Subcutaneous
Adipose Tissue
Abdominal subcutaneous adipose tissue was inversely associ-
ated with TPS extent in Models 1 and 2 (P < .05 and P < .01, re-
spectively) among HIV-infected men (P < .05 and P < .01,
respectively); no significant associations between aSAT and
coronary plaque extent were apparent in HIV-uninfected
men. There was a significant interaction by HIV serostatus be-
tween aSAT amount and MP extent in both Models (P < .05);
among HIV-infected men aSAT was negatively associated
with MP extent, and among HIV-uninfected aSATwas positive-
ly associated with MP extent, but neither association was statis-
tically significance. Although tSAT amount was generally not
associated with the extent of coronary plaque of any type
in Model 1, tSAT was inversely associated with extent of
CAC (P < .05) and with TPS extent (P < .05) in Model 2 with
no interaction by HIV serostatus.
DISCUSSION
In this well characterized group of men who underwent coro-
nary CT imaging, we found several associations between ana-
tomic fat depot volumes and subclinical coronary plaque
presence and extent; some of these differed by HIV serostatus
and by coronary plaque type. In general, HIV-infected men
had less subcutaneous fat (in both the abdomen and thigh)
and more VAT than HIV-uninfected men. In analytic models
that adjusted for age, race, CVD risk factors, and BMI, VAT
was positively associated with a greater likelihood of NCP pres-
ence among HIV-infected men (a plaque type previously shown
in this cohort to exist in excess among HIV-infected men) but
not among HIV-uninfected men. In similarly adjusted models,
less aSAT was associated with a greater extent of total plaque
(TPS) among HIV-infected men but not HIV-uninfected men.
Our finding of an association between increased VAT and the
presence of NCP among HIV-infected persons is unique.
Among HIV-infected men, VAT amounts were greater than
HIV-uninfected men among normal weight and overweight
men but not among obese men. Because HIV-infected men
were more likely than HIV-uninfected men to have NCP, to
have greater VAT volumes (except among obese men), and to
demonstrate an association between greater VAT volume and
NCP, this raises the possibility of a VAT/NCP relationship
among HIV-infected men. Visceral adipose tissue amount has
been positively correlated with CAC amount in 1 Italian cohort
of HIV-infected persons [10], but we did not find associations
between VAT amount and plaque types other than NCP in our
cohort. Reasons for between-cohort discrepant plaque associa-
tion with VAT are not clear, but they may include the following:
(1) other cohorts have not undertaken measurements of sub-
clinical plaque types other than CAC; (2) patients in the Italian
cohort attended an HIV metabolic clinic and had a high prev-
alence of lipodystrophy (including increased VAT) and other
metabolic abnormalities; and (3) it is possible that NCP repre-
sents newer (younger) plaque that, over time, evolves into more
CP. Although cross-sectional data such as ours do not allow
conclusions to be drawn as to pathophysiologic sequence of
events, the presence of an association between VAT volume
and NCP presence in our data but not between VAT volume
and NCP extent raises the possibility that VAT amount may
be linked to NCP initiation but not to NCP progression.
In our cohort, HIV-infected men had more NCP than HIV-
uninfected men [24];NCP may represent younger plaque that is
more prone to rupture than CP. Although the extent to which
NCP presence was accounted for or modified by the presence or
amount of VAT is unclear, adjustment for VAT did not dimin-
ish differences in NCP presence by HIV serostatus (data not
shown). Although the extent to which VAT volume comprises
a risk for NCP formation is not evaluable in this cross-sectional
study, clinical factors associated with increased VAT are also
linked with CAD risk. In 1 cohort of HIV-infected persons,
VAT amount was independently associated with increased mor-
tality [31]. We are not aware of general population-based stud-
ies correlating VAT amount with NCP presence or extent.
Evaluation of VAT amount in association with CVD clinical
events comprises an area deserving of future study.
Although factors consequent to HIV infection (eg, systemic
inflammation and/or immune activation) comprise unique
risks for plaque formation, including vascular endothelial func-
tion impairment [32], the extent to which these factors are
common to the etiology of both NCP and VAT among HIV-
infected men or account for relationships between the 2 is
unclear. Other work from our group will explore associations
Figure 1. Adjusted odds ratios of presence of noncalcified plaque score (NCP) >0
per 10 units increase in abdomen visceral fat volume by human immunodeficiency
virus (HIV) serostatus from multiple logistic regression. Factors adjusted for in regres-
sion models included age, race, body mass index, cumulative pack years of cigarette
smoking, use of antihypertension medications, systolic blood pressure among per-
sons who did not use antihypertensives, use of antidiabetic medications, fasting
glucose level among persons who did not use antidiabetic medications, use of
lipid-lowering medications, high-density lipoprotein, and low-density lipoprotein levels
among persons not receiving lipid-lowering medications.
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Table 5. Associations Between Extent of Coronary Plaque (Among Men With Plaque Present) and Body Fat Depotsa
Plaque Type, Analytic Model
Visceral Adipose Tissue Abdominal Subcutaneous Adipose Tissue Thigh Subcutaneous Adipose Tissue
All HIV+ HIV− All HIV+ HIV− All HIV+ HIV−
Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE)
CAC N= 486 N = 314 N = 172 N = 486 N = 314 N = 172 N = 487 N = 314 N = 173
Model 1 0.01 (0.01) 0.002 (0.01) 0.01 (0.02) −0.001 (0.01) 0.003 (0.01) −0.001 (0.01) −0.04 (0.03) −0.01 (0.04) −0.05 (0.04)
Model 2 0.01 (0.01) −0.001 (0.01) 0.02 (0.02) −0.01 (0.01) −0.0001 (0.01) −0.01 (0.02) −0.08* (0.04) −0.03 (0.05) −0.11 (0.06)
Noncalcified Plaque (NCP) N = 423 N = 277 N = 146 N = 423 N = 277 N = 146 N = 423 N = 277 N = 146
Model 1 0.003 (0.004) −0.004 (0.01) 0.01 (0.01) −0.002 (0.003) −0.004 (0.003) 0.003 (0.01) −0.01 (0.01) −0.02 (0.02) 0.01 (0.02)
Model 2 0.003 (0.01) −0.004 (0.01) 0.01 (0.01) −0.01 (0.01) −0.01 (0.01) −0.004 (0.01) −0.02 (0.02) −0.02 (0.02) −0.03 (0.03)
Calcified Plaque (CP) N = 251 N = 148 N = 103 N = 251 N = 148 N = 103 N = 251 N = 148 N = 103
Model 1 −0.001 (0.01) −0.001 (0.01) −0.001 (0.01) 0.001 (0.004) 0.01 (0.01) −0.003 (0.01) −0.01 (0.02) 0.0003 (0.03) −0.03 (0.03)
Model 2 −0.004 (0.01) −0.01 (0.01) −0.002 (0.01) −0.002 (0.01) 0.01 (0.01) −0.01 (0.01) −0.04 (0.02) −0.02 (0.03) −0.06 (0.04)
Mixed Plaque (MP) N = 234 N = 151 N = 83 N = 234 N = 151 N = 83 N = 235 N = 151 N = 84
Model 1 0.003 (0.01) 0.01 (0.01) −0.002 (0.01) −0.002b (0.004) −0.01 (0.01) 0.01 (0.01) −0.001 (0.02) −0.02 (0.03) 0.02 (0.03)
Model 2 0.002 (0.01) 0.02 (0.01) −0.02 (0.01) −0.01b (0.01) −0.02 (0.01) 0.002 (0.01) −0.02 (0.02) −0.02 (0.03) −0.02 (0.04)
Total Plaque Score N = 538 N = 337 N = 201 N = 538 N = 337 N = 201 N = 539 N = 337 N = 202
Model 1 0.002 (0.01) −0.001 (0.01) 0.01 (0.01) −0.01* (0.003) −0.01* (0.004) 0.001 (0.01) −0.02 (0.01) −0.02 (0.02) −0.004 (0.02)
Model 2 0.002 (0.01) 0.001 (0.01) −0.0002 (0.01) −0.01** (0.004) −0.02** (0.01) −0.01 (0.01) −0.04* (0.02) −0.03 (0.02) −0.05 (0.03)
Abbreviations: BMI, body mass index; CAC, coronary artery calcium score; CP, calcified plaque score; CV, cardiovascular; HIV, human immunodeficiency virus; MP, mixed plaque score; NCP, noncalcified plaque score; SE, standard error.
a Point estimates represent magnitude and direction of fat/plaque relationships, with significant relationships (P < .05) in bold. Model 1 adjusted for age, race, CV risk factors. Model 2 adjusted for age, race, CV risk factors, and BMI. Estimates represent mean
change in log-plaque score per 10-units increase in fat volume.
b HIV interaction P < 0.05.
*P < .05; **P < .01.
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between anatomic fat depots and coronary plaque, systemic
inflammation, and immune activation.
Our findings of lesser subcutaneous fat volume, aSAT, and
tSAT (lipoatrophy) in association with greater overall plaque ex-
tent among HIV-infected persons complement findings from
other cohorts reporting associations between HIV-related lipoa-
trophy and risk for CP [10] and Framingham Risk Score [33].
Factors known to increase CAD risk have been associated with
HIV-related lipoatrophy; these include insulin resistance [3, 34]
and pro-atherogenic hyperlipidemia [1], suggesting the possibil-
ity of a causal pathway. These findings may represent long-term
adverse effects of prior thymidine analog reverse-transcriptase
drug exposure, which are not generally reversible after drug
discontinuation.
We noted that regardless of HIV serostatus, less tSAT was as-
sociated with greater total coronary plaque (TPS) amount and
CAC score. Although our findings of lower median aSAT and
tSAT volumes among HIV-infected than uninfected men, re-
gardless of BMI, were not surprising, we are not aware of
other reports that have linked lower peripheral fat per se with
subclinical atherosclerosis in the general population. One report
has linked greater SAT to increased CAC amounts [35]; another
has linked reductions in glycation end-production expression in
SAT, which is related to lower SAT volume, to increased overall
CAD risk [36]. Again, in the context of this cross-sectional
study, no causal relationship between amounts of subcutaneous
fat and coronary plaque can be established.
Although feasibly anatomic fat changes may be associated
with increased coronary plaque risk through known CVD-
associated comorbidities, such as insulin resistance and pro-
atherogenic patterns of hyperlipidemia (both more common
among HIV-infected persons), other paths between “metaboli-
cally active” fat and coronary plaque formation may exist. Data
exist suggesting that, despite the fact mitochondrial disturbanc-
es are similar in VAT and SAT, there is differential induction of
pro-inflammatory signaling in VAT compared with SAT and
decreased adipogenic gene expression in SAT but not VAT;
these differences may result in wasting in SAT but not VAT
[23]. Whether or not these same factors influence differential
associations between fat depots and specific coronary plaque
types is unclear.
Persons with greater VAT and less SAT may eventually be
shown to comprise a population to be targeted for more aggres-
sive CVD screening and risk factor reduction. Our findings may
suggest that factors known to be associated with increased CVD
risk in the general population, such as the associations between
VAT, increased hyperlipidemia, and insulin resistance, are also
operative among HIV-infected persons, although mechanisms
mediating associations between VAT and CVD may differ by
HIV serostatus. Although strategies to reduce CVD risk in the
general population are valuable among HIV-infected persons,
if unique CVD risk factors exist in this population, then
established CVD risk assessment and reduction strategies may
be insufficient, as recent data profiling the underprediction of
CVD events using standard CVD risk prediction equations
[37] suggest. Whether or not unique anatomic fat or coronary
plaque relationships among HIV-infected persons may inform
the CVD risk assessment process in this group is unclear but
deserving of further study.
Limitations to our study exist. A cross-sectional study cannot
directly assess causality between fat depot volume and coronary
plaque. In general, our control group (HIV-uninfected men)
was older and less likely to be black than the HIV-infected
men. In addition, we did evaluate associations between coro-
nary plaque and other fat depots such as epicardial or liver
fat, a subject of other work from our group. Furthermore, we
did not have the statistical power to assess anatomic fat or
coronary plaque associations in relationship to specific ART ex-
posure. Missing data regarding risk factors involving approxi-
mately 10% of study participants required imputation; it is
feasible that such imputation may have impacted the results. Fi-
nally, this is a study that included only men; the extent to which
our findings can be generalizable to women is unclear.
CONCLUSIONS
In summary, we identified unique associations between ana-
tomic fat depot volumes and coronary plaque that differed by
HIV serostatus. In particular, our findings of associations be-
tween greater VAT volume and NCP presence among HIV-
infected men and between subcutaneous fat depletion and
some types of coronary plaque, particularly (but not exclusive-
ly) among HIV-infected men, are novel. The extent to which
this information may be useful in future study evaluating the
interplay between visceral and subcutaneous fat volumes with
risks for and occurrence of CVD among HIV-infected persons
is not yet clear. Further work is necessary to better ascertain fac-
tors that maymediate the impact of anatomic fat upon CVD path-
ogenesis with the hope such work can ultimately help inform the
development of improved CVD clinical screening and therapeutic
interventions for both HIV-infected and uninfected persons.
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